- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02853630
A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus
A Multicentric, Randomized, Open Label Study on Comparison of Pancreatic Beta Cell Recovery and Preservation in Type 2 Diabetic Patients Treated With DPP-4 Inhibitor (Vildagliptin) and Metformin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The subjects will be invited to the study center from the local population who are willing to participate in the trial. Each subject will be informed both orally and in writing about the study prior to inclusion in the study and only the subjects who give written informed consent will be included. The selection of the subjects is based on the inclusion and exclusion criteria defined in the protocol. The selected subjects will be given a screening number and subjected to screening procedure to find out eligible candidates for enrollment. The screening procedure includes obtaining subject's anthropometric data, baseline symptomatology, medical history, physical examination, laboratory investigations like blood glucose (fasting, 30min & 2hr after meal), HbA1c, ^Plasma insulin (fasting, 30min & 2hr after meal), ^2hr C peptide, Serum Amylase, Lipase, Urea, Creatinine, Gamma-glutamyl transferase (GGT), Urine albumin/creatinine ratio and urine pregnancy (if applicable).
The selected subjects after the screening procedure will be given a subject number and randomized between two arms. In Arm 1 they will be advised to take Vildagliptin 100mg daily for 96 weeks. In Arm 2 they are assigned Metformin (1000mg - 2500 mg/ day according to physician's preference for 96 weeks and all the subjects will be asked to come for follow up on week 12, week 24, week 48, week 72 and week 96. Subjects will be given sufficient quantity of study drugs. They will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner or Metformin tablets as per instructions given by the physician. Subjects will be instructed to maintain the record of dosing details in the patient diary.
Blood samples will be taken for the investigations such as blood glucose (fasting, 30min & 2hr after meal), HbA1c, Plasma insulin (fasting, 30min & 2hr after meal), C peptide (2hr after meal), fasting serum Amylase, Lipase, Urea, Creatinine, GGT, Urine albumin/creatinine ratio and Urine pregnancy test(if required) as specified in visit chart below. There will be three telephonic visits on week 36, week 60 and week 84. During those visits subject will be inquired about the health status over the phone and the drugs for the next three months will be dispensed by courier or delivered at home by the coordinator.
If the glycaemic control is constantly not satisfactory (HbA1c ≥ 8.5%) from visit 3, a rescue drug (Glimepiride) will be added to both arms and all the clinical and biochemical test will be done as per visit chart. With Glimepiride if the A1C is >9% insulin will be added and the subject will be withdrawn from the study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Karnataka
-
Bangalore, Karnataka, India, 560 078
- Jnana Sanjeevini Medical Centre
-
-
Maharashtra
-
Pune, Maharashtra, India, 411 005
- Vikas Pai Research Foundation
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600 019
- Singhvi Health Centre
-
Chennai, Tamil Nadu, India, 600029
- Dr V.Seshiah Diabetes research Institute, Dr V.Balaji Diabetes care centre
-
Madurai, Tamil Nadu, India, 625 020
- Arthur Asirvatham Hospital
-
Tiruvannamalai, Tamil Nadu, India, 606 603
- Ramana Maharishi Rangammal Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Newly Diagnosed Type 2 Diabetes Mellitus patients not receiving any medication for diabetes
- HbA1c ranging from 7.0% to ≤ 8.5%
- Body Mass Index (BMI) ≥ 19.0 to ≤ 25.0 kg/m2
- Male and female subjects of age between 20 - 60 years shall be selected
- Adult subjects willing to give informed consent
- Subject must be available for and willing to attend all evaluation visits
- Willingness to follow the protocol requirements as evidenced by written informed consent
- Subject must have access to telephone for calling into the clinical center as part of test product compliance
Exclusion Criteria:
- Type 1 diabetes
- BMI ≤18.99 kg/m2 or> 25 kg/m2
- Presence of severe vascular complications
- Indications for use of insulin
- Elevated serum levels of lipase and amylase (>1.5 ULN)
- Gamma-glutamyltransferase >2 times upper limit of normal (ULN) at Visit1, confirmed by repeated measure within 3 working days
- Urine albumin: creatinine ratio (UACR) >1800 mg/g (>203.4 mg/mmol)
- Subjects below the age of 20 years and above the age of 60 years
- History of any drug abuse in the past 12 months
- History of hypersensitivity to study drugs and related drugs or excipients in the formulation.
- History of allergy to vegetables and or food substances and or any other manifestations suggestive of hypersensitivity reactions
- Subject who is not willing to participate in the study
- Clinically significant abnormal laboratory results at screening.
- Subject is being treated for severe active infection of any type
- A female subject who is breast-feeding, pregnant, or intends to become pregnant during the study
- Subject with clinically relevant uncontrolled medical condition (e.g hematologic renal hepatic neurology cardiac or respiratory)
- Subject has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years
- Participating in a clinical research trial within 30 days prior to screening
- Donated blood 3 months prior to first study visit and during the study period
- Individuals who are cognitively impaired and or who are unable to give informed consent
- Known HIV or Hepatitis B or C positive
- Any other health or mental condition that in the Investigator's opinion may adversely affect the subjects ability to complete the study or its measures or that may pose significant risk to the subject
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Metformin
Tablet Metformin 1000 - 2500 mg/day for 96 weeks
|
Participant will be instructed to take Metformin tablets as per instructions given by the physician.
|
Experimental: Vildagliptin
Tablet Vildagliptin 100mg/day for 96 weeks
|
Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Insulin secretion rate
Time Frame: Baseline and 96 weeks
|
To compare the effects of Vildagliptin versus Metformin on Pancreatic beta cell function in type 2 diabetic subjects as measure by Insulin secretion rate (ISR) relative to glucose0-2hr (pmol/min/m2/mmol/L)
|
Baseline and 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in HbA1c reduction
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of Percent HbA1c reduction
|
Baseline and 96 weeks
|
Changes in C peptide response
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of C peptide response
|
Baseline and 96 weeks
|
Changes in Insulin to glucose ratio
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of insulin to glucose ratio
|
Baseline and 96 weeks
|
Changes in Fasting plasma glucose
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of reduction in fasting plasma glucose
|
Baseline and 96 weeks
|
Changes in 2hr postprandial plasma glucose
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of reduction in 2hr postprandial plasma glucose
|
Baseline and 96 weeks
|
Changes in Insulin sensitivity
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of improvement in insulin sensitivity
|
Baseline and 96 weeks
|
Changes in Oral disposition index
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of improvement in oral disposition index
|
Baseline and 96 weeks
|
Percentage of subjects reaching HbA1c ≤ 6.5%
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of percentage of subjects reaching the glycemic target of HbA1c ≤ 6.5%
|
Baseline and 96 weeks
|
Percentage of subjects reaching HbA1c ≤ 7.0%
Time Frame: Baseline and 96 weeks
|
Effect of Vildagliptin versus Metformin based treatment on glycaemic variables in terms of percentage of subjects reaching the glycemic target of HbA1c ≤ 7.0%
|
Baseline and 96 weeks
|
Number of participant treated related to adverse event
Time Frame: Baseline and 96 weeks
|
Number of adverse event observed in both Vildagliptin and Metformin treatment group will be assessed
|
Baseline and 96 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Vildagliptin
Other Study ID Numbers
- CLAF237AIN04
- CTRI/2014/01/004301 (Other Identifier: Clinical Trail Registry - India)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on TYpe 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Charles University, Czech RepublicCompleted
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland